Literature DB >> 12939232

5,6-epoxyeicosatrienoic acid mediates the enhanced renal vasodilation to arachidonic acid in the SHR.

Silvia I Pomposiello1, John Quilley, Mairead A Carroll, John R Falck, John C McGiff.   

Abstract

We have shown a cytochrome P450-dependent renal vasodilator effect of arachidonic acid in response to inhibition of cyclooxygenase and elevation of perfusion pressure, which was enhanced in the spontaneously hypertensive rat (SHR) and linked to increased production of and/or responsiveness to epoxyeicosatrienoic acids (EETs). In the SHR, vasodilation elicited by low doses of arachidonic acid was attenuated by the nitric oxide synthase inhibitor Nw-nitro-L-arginine (50 micromol/L), whereas the responses to high doses were unaffected. Inhibition of epoxygenases with miconazole (0.3 micromol/L) in the presence of Nw-nitro-L-arginine greatly reduced the renal vasodilator response to all doses of arachidonic acid. Tetraethylammonium (10 mmol/L), a nonselective K+ channel blocker, abolished the nitric oxide-independent renal vasodilator effect of arachidonic acid as well as the vasodilator effect of 5,6-EET, confirming that EET-dependent vasodilation involves activation of K+ channels. Under conditions of elevated perfusion pressure (200 mm Hg) and cyclooxygenase inhibition, 5,6-EET, 8, 9-EET, and 11,12-EET caused renal vasodilatation in both SHR and Wistar-Kyoto rats (WKY), whereas 14,15-EET produced vasoconstriction. 5,6-EET was the most potent renal vasodilator of the EET regioisomers in the SHR by a factor of 4 or more. In the SHR, 5,6-EET- and 11,12-EET-induced renal vasodilatation was >2-fold greater than that registered in WKY. Thus, the augmented vasodilator responses to arachidonic acid in the SHR is through activation of K+ channels, and 5,6-EET is the most likely mediator.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12939232     DOI: 10.1161/01.HYP.0000090095.87899.36

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  14 in total

Review 1.  Epoxides and soluble epoxide hydrolase in cardiovascular physiology.

Authors:  John D Imig
Journal:  Physiol Rev       Date:  2012-01       Impact factor: 37.312

Review 2.  Endothelial control of vasodilation: integration of myoendothelial microdomain signalling and modulation by epoxyeicosatrienoic acids.

Authors:  David C Ellinsworth; Scott Earley; Timothy V Murphy; Shaun L Sandow
Journal:  Pflugers Arch       Date:  2013-06-08       Impact factor: 3.657

Review 3.  Vascular pharmacology of epoxyeicosatrienoic acids.

Authors:  Sandra L Pfister; Kathryn M Gauthier; William B Campbell
Journal:  Adv Pharmacol       Date:  2010

4.  15-Lipoxygenase metabolites contribute to age-related reduction in acetylcholine-induced hypotension in rabbits.

Authors:  Nitin T Aggarwal; Kathryn M Gauthier; William B Campbell
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-05-02       Impact factor: 4.733

5.  Epoxyeicosatrienoic acids affect electrolyte transport in renal tubular epithelial cells: dependence on cyclooxygenase and cell polarity.

Authors:  Rolf M Nüsing; Horst Schweer; Ingrid Fleming; Darryl C Zeldin; Markus Wegmann
Journal:  Am J Physiol Renal Physiol       Date:  2007-05-09

6.  Role of TRPV1 channels in renal haemodynamics and function in Dahl salt-sensitive hypertensive rats.

Authors:  Jianping Li; Donna H Wang
Journal:  Exp Physiol       Date:  2008-04-10       Impact factor: 2.969

7.  Stimulation of rat erythrocyte P2X7 receptor induces the release of epoxyeicosatrienoic acids.

Authors:  H Jiang; A G Zhu; M Mamczur; J R Falck; K M Lerea; J C McGiff
Journal:  Br J Pharmacol       Date:  2007-06-11       Impact factor: 8.739

8.  Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo.

Authors:  Jun-Yan Liu; See-Hyoung Park; Christophe Morisseau; Sung Hee Hwang; Bruce D Hammock; Robert H Weiss
Journal:  Mol Cancer Ther       Date:  2009-08-11       Impact factor: 6.261

9.  Pharmacokinetic optimization of four soluble epoxide hydrolase inhibitors for use in a murine model of inflammation.

Authors:  Jun-Yan Liu; Hsing-Ju Tsai; Sung Hee Hwang; Paul D Jones; Christophe Morisseau; Bruce D Hammock
Journal:  Br J Pharmacol       Date:  2009-01-13       Impact factor: 8.739

10.  Increased GFR and renal excretory function by activation of TRPV1 in the isolated perfused kidney.

Authors:  Jianping Li; Donna H Wang
Journal:  Pharmacol Res       Date:  2008-02-02       Impact factor: 7.658

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.